- The report contains detailed information about Transition Therapeutics Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Transition Therapeutics Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Transition Therapeutics Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Transition Therapeutics Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Transition Therapeutics Inc. business.
About Transition Therapeutics Inc.
Transition Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of therapeutic agents for various disease indications.
The company has three primary technologies in development, including ELND005 (AZD-103) for the treatment of Alzheimers disease; TT-301 and TT-302, which can have a therapeutic effect on diseases including arthritis, Alzheimers disease, traumatic brain injury, intracerebral haemorrhage, and others; and TT401/402 for the treatment of diabetes.
The company is developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. The Alzheimers disease primary product, ELND005 (AZD-103), is part of an emerging class of disease-modifying drugs that have the potential to both reduce disease progression and improve symptoms, such as diminished cognitive function. The company and its development partner, Elan Pharma International Limited (Elan) have performed multiple Phase I studies evaluating the safety, tolerability, and pharmacokinetic profile of ELND005 (AZD-103) in healthy volunteers. The company completed a Phase II clinical study of ELND005 (AZD-103) in patients with Alzheimers disease.
TT-301 / TT-302
The companys primary drug candidates in development are TT-301 and TT-302. These drug candidates are derived from a diligent drug design program engineered to produce compounds optimized to target inhibiting pro-inflammatory cytokines in the brain and periphery.
TT-401 / TT-402
In March, 2010 the company acquired the rights to a series of preclinical compounds from Eli Lilly and Company (Lilly) in the area of diabetes. Under the licensing and collaboration agreement, Transition receives worldwide rights to develop and potentially commercialize a class of compounds.
The primary compound, TT-401, is a dual agonist of GLP-1 and glucagon receptors. In preclinical diabetes models, TT-401 has shown potential to provide glycemic control and other beneficial effects, including weight loss. The company is performing preclinical development activities to advance this drug candidate forward as a therapy for type 2 diabetes.
The companys product, ELND005 (AZD-103) is produced by Albany Molecular Research Inc. (New York) and Abbott Laboratories (Illinois). The company has contracted Piramal Healthcare (Canada) Limited to produce active ingredient for TT-301/ TT-302. It has contracted Polypeptide Laboratories A/S of Denmark to produce the active ingredient for TT-401.
In September 2010, the company announced that a clinical study of gastrin analogue TT-223 in combination with Eli Lilly and Company proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. The companies continue to work diligently on this program and the licensing arrangement is unaffected by the TT-223 clinical study results.
In December 2010, Transition Therapeutics Inc. and Elan Corp. plc have mutually agreed to modify their collaboration agreement for the development and commercialization of ELND005.
The company was founded in 1987. It was formerly known as Transition Therapeutics and Diagnostics, Inc. and changed its name to Transition Therapeutics, Inc. in 2000.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. TRANSITION THERAPEUTICS INC. COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. TRANSITION THERAPEUTICS INC. BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. TRANSITION THERAPEUTICS INC. SWOT ANALYSIS
4. TRANSITION THERAPEUTICS INC. FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. TRANSITION THERAPEUTICS INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Transition Therapeutics Inc. Direct Competitors
5.2. Comparison of Transition Therapeutics Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Transition Therapeutics Inc. and Direct Competitors Stock Charts
5.4. Transition Therapeutics Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Transition Therapeutics Inc. Industry Position Analysis
6. TRANSITION THERAPEUTICS INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. TRANSITION THERAPEUTICS INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. TRANSITION THERAPEUTICS INC. ENHANCED SWOT ANALYSIS2
9. CANADA PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. TRANSITION THERAPEUTICS INC. IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. TRANSITION THERAPEUTICS INC. PORTER FIVE FORCES ANALYSIS2
12. TRANSITION THERAPEUTICS INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Transition Therapeutics Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Transition Therapeutics Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Transition Therapeutics Inc. Major Shareholders
Transition Therapeutics Inc. History
Transition Therapeutics Inc. Products
Revenues by Segment
Revenues by Region
Transition Therapeutics Inc. Offices and Representations
Transition Therapeutics Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Transition Therapeutics Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Transition Therapeutics Inc. Capital Market Snapshot
Transition Therapeutics Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Transition Therapeutics Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Transition Therapeutics Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Transition Therapeutics Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Transition Therapeutics Inc. 1-year Stock Charts
Transition Therapeutics Inc. 5-year Stock Charts
Transition Therapeutics Inc. vs. Main Indexes 1-year Stock Chart
Transition Therapeutics Inc. vs. Direct Competitors 1-year Stock Charts
Transition Therapeutics Inc. Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?